HIV Infections Clinical Trial
Official title:
Health and Justice: A Continuum of Care for HIV and SU for Justice-Involved Young Adults (PHASE 2)
Verified date | December 2022 |
Source | New York State Psychiatric Institute |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This research study proposes to embed HIV testing outreach workers from a young adult focused medical and HIV treatment program into an alternative sentencing program to deliver a new service delivery model (Link2CARE) that integrates evidence-based protocols for justice-involved young adults to: a) promote HIV and STI testing, and HIV and SU risk screening, b) provide onsite intervention, and c) cross-system linkage to HIV, STI, and SU care. Phase 1 has already been completed. In phase 1, the intervention components were adapted for use among justice involved young adults and the resulting protocols were piloted with justice involved young adults, finalizing the resulting 4-session Link2CARE intervention. In phase 2, we will test Link2CARE among N=450 justice-involved young adults enrolled at the alternative sentencing program and conduct process evaluations with N=15 alternative sentencing program staff.
Status | Completed |
Enrollment | 307 |
Est. completion date | December 1, 2022 |
Est. primary completion date | September 30, 2021 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years to 80 Years |
Eligibility | Young Adults Inclusion Criteria: - Between 18-24 years of age - Currently enrolled at the alternative to sentencing program - Conversant in English - Engaged in any unprotected or vaginal sexual activity (in the past 12 months) Exclusion Criteria: - Cognitively unable to complete the interview - HIV positive Alternative to Sentencing Staff Inclusion Criteria: - Currently employed at the alternative to sentencing program - Between ages of 18-80 Exclusion Criteria: - None |
Country | Name | City | State |
---|---|---|---|
United States | Kings County Criminal Court | Brooklyn | New York |
Lead Sponsor | Collaborator |
---|---|
New York State Psychiatric Institute | Center for Court Innovation, Columbia University, National Institute on Drug Abuse (NIDA), The National Center on Addiction and Substance Abuse at Columbia University |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Number of HIV+ Young Adults Referred to HIV Treatment | measured by Health Coach report in the Health Coach logs and participant report in the "HIV Referral" section of the questionnaires | at 3-, 6-, and 12-month follow-ups | |
Other | Number of HIV+ Young Adults Attending at Least One Treatment Appointment | measured by Health Coach report in the Health Coach logs and participant report in the "HIV Treatment" section of the questionnaires | at 3-, 6-, and 12-month follow-ups | |
Other | Number of Young Adults Behaviorally PrEP Eligible Referred to PrEP/Medical Care | measured by Health Coach report in the Health Coach logs and participant report in the "PrEP Referral" section of the questionnaires | at 3-, 6-, and 12-month follow-ups | |
Other | Number of Young Adults Behaviorally PrEP Eligible Attending at Least One HIV Care Appointment | measured by Health Coach report in the Health Coach logs and participant report in the "PrEP Uptake" section of the questionnaires | at 3-, 6-, and 12-month follow-ups | |
Primary | Total Number of Unprotected Anal and Vaginal Sex Occasions in Past 3 Months | measured by participant report in the "Sexual Risk" section of the questionnaires | at 12-month follow-up | |
Secondary | Frequency of Young Adults Substance Use in Past 30 Days | measured by participant report in the "Substance Use" section of the questionnaires | at 3-, 6-, and 12-month follow-ups | |
Secondary | Number of Young Adults Referred to Substance Use Treatment | measured by Health Coach report in the Health Coach logs and participant report in the "Substance Use Referral" section of the questionnaires | at 3-, 6-, and 12-month follow-ups | |
Secondary | Number of Young Adults Attending Intake Plus One Treatment Session | measured by Health Coach report in the Health Coach logs and participant report in the "Substance Use Treatment" section of the questionnaires | at 3-, 6-, and 12-month follow-ups | |
Secondary | Acceptance of STI Testing (Yes/no) | measured by Health Coach report in the "Session 1 Sexual Risk" questionnaire | at day 1 of enrollment | |
Secondary | Any STI Testing | measured by participant report in the "STI Testing" section of the questionnaires | between 6- and 12-month follow-ups | |
Secondary | Number of STI+ Young Adults Referred to STI Treatment | measured by the Health Coach report in the Health Coach Logs and participant report in the "STI Referral" section of the questionnaires | at 3-, 6-, and 12-month follow-ups | |
Secondary | Number of STI+ Young Adults Attending 1 or More Treatment Appointments | measured by Health Coach report in the Health Coach logs and participant report in the "STI Treatment" section of the questionnaires | at 3-, 6-, and 12-month follow-ups | |
Secondary | Acceptance of HIV Testing (Yes/no) | measured by Health Coach report in the "Session 1 Sexual Risk" questionnaire | at day 1 of enrollment | |
Secondary | Any HIV Testing | measured by participant report in the "HIV Testing" section of the questionnaires | between 6-month and 12-month follow-ups |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05454514 -
Automated Medication Platform With Video Observation and Facial Recognition to Improve Adherence to Antiretroviral Therapy in Patients With HIV/AIDS
|
N/A | |
Completed |
NCT03760458 -
The Pharmacokinetics, Safety, and Tolerability of Abacavir/Dolutegravir/Lamivudine Dispersible and Immediate Release Tablets in HIV-1-Infected Children Less Than 12 Years of Age
|
Phase 1/Phase 2 | |
Completed |
NCT03067285 -
A Phase IV, Open-label, Randomised, Pilot Clinical Trial Designed to Evaluate the Potential Neurotoxicity of Dolutegravir/Lamivudine/Abacavir in Neurosymptomatic HIV Patients and Its Reversibility After Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide. DREAM Study
|
Phase 4 | |
Completed |
NCT03141918 -
Effect of Supplementation of Bioactive Compounds on the Energy Metabolism of People Living With HIV / AIDS
|
N/A | |
Recruiting |
NCT04579146 -
Coronary Artery Disease (CAD) in Patients HIV-infected
|
||
Completed |
NCT06212531 -
Papuan Indigenous Model of Male Circumcision
|
N/A | |
Active, not recruiting |
NCT03256422 -
Antiretroviral Treatment Taken 4 Days Per Week Versus Continuous Therapy 7/7 Days Per Week in HIV-1 Infected Patients
|
Phase 3 | |
Completed |
NCT03256435 -
Retention in PrEP Care for African American MSM in Mississippi
|
N/A | |
Completed |
NCT00517803 -
Micronutrient Supplemented Probiotic Yogurt for HIV/AIDS and Other Immunodeficiencies
|
N/A | |
Active, not recruiting |
NCT03572335 -
Systems Biology of Diffusion Impairment in Human Immunodeficiency Virus (HIV)
|
||
Completed |
NCT04165200 -
Fecal Microbiota Transplantation as a Therapeutic Strategy for Patients Infected With HIV
|
N/A | |
Recruiting |
NCT03854630 -
Hepatitis B Virus Vaccination in HIV-positive Patients and Individuals at High Risk for HIV Infection
|
Phase 4 | |
Terminated |
NCT03275571 -
HIV, Computerized Depression Therapy & Cognition
|
N/A | |
Completed |
NCT02234882 -
Study on Pharmacokinetics
|
Phase 1 | |
Completed |
NCT01618305 -
Evaluating the Response to Two Antiretroviral Medication Regimens in HIV-Infected Pregnant Women, Who Begin Antiretroviral Therapy Between 20 and 36 Weeks of Pregnancy, for the Prevention of Mother-to-Child Transmission
|
Phase 4 | |
Recruiting |
NCT05043129 -
Safety and Immune Response of COVID-19 Vaccination in Patients With HIV Infection
|
||
Not yet recruiting |
NCT05536466 -
The Influence of Having Bariatric Surgery on the Pharmacokinetics, Safety and Efficacy of the Novel Non-nucleoside Reverse Transcriptase Inhibitor Doravirine
|
N/A | |
Recruiting |
NCT04985760 -
Evaluation of Trimer 4571 Therapeutic Vaccination in Adults Living With HIV on Suppressive Antiretroviral Therapy
|
Phase 1 | |
Completed |
NCT05916989 -
Stimulant Use and Methylation in HIV
|
||
Terminated |
NCT02116660 -
Evaluation of Renal Function, Efficacy, and Safety When Switching From Tenofovir/Emtricitabine Plus a Protease Inhibitor/Ritonavir, to a Combination of Raltegravir (MK-0518) Plus Nevirapine Plus Lamivudine in HIV-1 Participants With Suppressed Viremia and Impaired Renal Function (MK-0518-284)
|
Phase 2 |